Actelion logo
|
|
public company | |
Industry | Pharmaceuticals/Biotech |
Founded | 1997 |
Founder | Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann |
Headquarters | Gewerbestrasse 16, Allschwil, Basel country, Switzerland |
Area served
|
Research and Development of medicines for unmet medical need |
Key people
|
Jean-Paul Clozel, Chief Executive Office Guy Braunstein, Global Clinical Development Otto Schwarz, Chief Operating Officer Nicholas Franco, Chief Business Officer André C. Muller, Chief Financial Officer |
Products | Tracleer, Ventavis, Zavesca, Veletri, Opsumit |
Revenue | 1,929 mio CHF |
457.3 mio CHF | |
390.6 mio CHF | |
Number of employees
|
2467 (January 2011) |
Website | www |
Actelion is a pharmaceuticals and bio-technology company established in December 1997, headquartered in Allschwil near Basel in Switzerland. Its CEO and co-founder is cardiologist Jean-Paul Clozel.
Actelion specializes in orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with venture capital provided through a syndicate including Atlas Venture, Sofinnova and HealthCap.
Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. The Swiss affiliate is located in Baden, the German affiliate in Freiburg, the Austrian one in Vienna, the French one in Paris and the UK affiliate is located in London
In 2006, the company established the Actelion Endothelin Research Award programme which supports selected clinical research projects.
In January 2017, Johnson & Johnson announced that it would purchase the company for $30 billion. Actelion's research and development unit would also be spun off after the acquisition.
Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases:
Late-stage drugs in development by Actelion include:
By January 2011, Actelion had a total of 2,467 employees, 392 in research, 640 in development and 1017 in sales and marketing. In 2010, Actelion's sales amounted to 1,929 million CHF.
Actelion's shares have been listed on the SIX Swiss Exchange (ticker symbol ATLN) since 2000 SWX Swiss Exchange Swiss Leader Index. In September 2008, Actelion shares began trading as part of the Swiss Market Index.